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High-throughput identification of 
peptide agonists against GPCRs by 
co-culture of mammalian reporter 
cells and peptide-secreting yeast 
cells using droplet microfluidics
Kenshi Yaginuma1, Wataru Aoki  1,2,3, Natsuko Miura4, Yuta Ohtani1, Shunsuke Aburaya  1,5,  
Masato Kogawa6,7, Yohei Nishikawa6,7, Masahito Hosokawa  3,8, Haruko Takeyama6,7,8 & 
Mitsuyoshi Ueda1,2
Since G-protein coupled receptors (GPCRs) are linked to various diseases, screening of functional 
ligands against GPCRs is vital for drug discovery. In the present study, we developed a high-throughput 
functional cell-based assay by combining human culture cells producing a GPCR, yeast cells secreting 
randomized peptide ligands, and a droplet microfluidic device. We constructed a reporter human cell 
line that emits fluorescence in response to the activation of human glucagon-like peptide-1 receptor 
(hGLP1R). We then constructed a yeast library secreting an agonist of hGLP1R or randomized peptide 
ligands. We demonstrated that high-throughput identification of functional ligands against hGLP1R 
could be performed by co-culturing the reporter cells and the yeast cells in droplets. We identified 
functional ligands, one of which had higher activity than that of an original sequence. The result 
suggests that our system could facilitate the discovery of functional peptide ligands of GPCRs.
G-protein coupled receptors (GPCRs) are seven-transmembrane receptors representing the largest membrane 
protein family in humans1. GPCRs play key roles in transmitting extracellular signals as intracellular responses1. 
Natural ligands for GPCRs are diverse. Most neurotransmitters2,3, autacoids4,5, and hormones6,7 act by binding to 
GPCRs. Since abnormal activities of GPCRs are linked to various human diseases, screening of drugs targeting 
GPCRs has become an important field of study. Indeed, approximately 50% of the drugs in the market act on 
signal transduction systems involving GPCRs, 30% of which act on GPCRs directly8,9. Based on the currently 
clarified functions of GPCRs, about 400 GPCRs are druggable8–11. However, drugs targeting GPCRs have been 
developed only for approximately 100 GPCRs10. Approximately 60 GPCRs among the 400 druggable GPCRs 
reportedly receive peptides as ligands10. Some of the GPCRs are associated with diseases such as type 2 diabetes, 
cancer, asthma, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), HIV, epilepsy, cardiovas-
cular disorders, or migraine10. Therefore, an approach that can identify drug candidates for peptide-activated 
GPCRs in a high-throughput manner would considerably facilitate drug discovery.
When searching for peptide-based drug candidates, functional assay systems are important methodologies 
for revealing novel functional ligands of GPCRs. For example, quantification of second messengers has been used 
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to quantify GPCR activities12. In addition, functional assay systems in which reporter genes are regulated by sec-
ond messenger response elements have also been reported12,13. For example, in a previous study, we constructed 
a hGLP1R/NLuc-293 reporter cell line13, which secretes NanoLuc14 in response to the activation of the human 
glucagon-like peptide 1 receptor (hGLP1R)15. Such a system facilitates easy and sensitive detection of GPCRs 
activities, in turn facilitating the identification of agonists or antagonists of target GPCRs.
In the search for novel peptide ligands, designing a ligand library is an important process. At present, various 
studies have employed display technologies in the construction of peptide libraries because they can easily con-
struct large peptide libraries at low costs16–19. However, in the display systems, steric hindrance could adversely 
affect the functions of the displayed peptides20. Secretion of peptides could be an alternative promising strategy 
for addressing the problem13 (Fig. 1a). Steric hindrance does not affect secreted peptides, which facilitates the 
evaluation of the inherent activities of the peptides. In a previous study, we developed a functional assay system 
using yeast cells secreting peptide ligands13. Such an approach permits the easy construction of a soluble peptide 
ligand library at relatively low cost.
Although the construction of peptide libraries has become simple, many studies have performed low through-
put plate-based assays for evaluating the activities of peptide libraries12,13. Droplet microfluidic devices could be 
Figure 1. Schematic of the high-throughput functional cell-based assay using droplet microfluidics. (a) 
Functional cell-based assay using GPCR-producing reporter cells and ligand-secreting yeast cells. When 
peptide ligands secreted by yeast cells activate GPCRs produced by HEK293, a reporter gene is activated via 
cAMP response element (CRE). (b) High-throughput functional cell-based assay using droplet microfluidics. 
The reporter cells and the yeast cells secreting randomized peptide ligands are encapsulated in droplets and co-
cultured. When a randomized peptide ligand secreted by a single yeast cell activates the reporter cell, resulting 
in the production of reporter proteins (LacZ), a droplet emits strong fluorescence. The fluorescent droplets 
are isolated, and the yeast cells producing functional peptide ligands are cultured on a plate medium. Finally, 
sequences of the functional peptide ligands are determined using DNA sequencing.
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alternative promising tools for high-throughput assays21. Droplet microfluidic devices have micrometer-sized 
flow paths22, and can produce monodisperse droplets in the nanometer to micrometer diameter range at tens 
of thousands of droplets per second rates22. Droplet microfluidics is an effective approach for screening large 
libraries because it is compatible with fluorescence-activated sorting23,24. It has been reported that the cultivation 
of microorganisms and mammalian culture cells is possible using droplets25,26. In addition, various assays can be 
performed using droplets: screening of functional T-cell receptors27, screening of hybridoma cells which secrete 
functional antibodies28, and drug discovery and genomic applications29,30.
We have previously developed a functional assay system using combined mammalian cells, which produce 
NanoLuc in response to the activation of hGLP1R and yeast cells that secrete randomized peptides13; however, its 
throughput was low because we carried out functional assays using 96-well plates. In the present study, we attempt 
to construct a novel high-throughput cell-based assay for the identification of peptide ligands (Fig. 1b). To 
develop the system, we constructed a mammalian reporter cell line (hGLP1R/LacZ-293), which produces LacZ 
in response to the activation of hGLP1R as a model. Replacement of NanoLuc with LacZ enables high-throughput 
evaluation using fluorescence observation. In addition, we used a droplet microfluidics device to facilitate mas-
sively parallel functional assays. By combining an hGLP1R/LacZ-293 reporter cell line, a yeast library secreting 
randomized hGLP1R ligands, and a droplet microfluidic device, we identified functional ligands for hGLP1R. The 
methodology could be a useful platform for the discovery of novel peptide ligands of GPCRs.
Results
Construction of a LacZ reporter cell line for functional assay of hGLP1R. We constructed a human 
reporter cell line (hGLP1R/LacZ-293), which constitutively produces human GLP1R (hGLP1R), and inducibily 
secretes LacZ in response to the activation of hGLP1R. First, we compared hGLP1R/LacZ-293 and hGLP1R/
NLuc-293 cell lines constructed in a previous study13. hGLP1R/NLuc-293 is a cell line that produced NanoLuc in 
response to the activation of hGLP1R. We cultured the cell lines in Dulbecco’s modified Eagle’s medium (DMEM) 
with or without 30 nM exendin-4 (Ex4), a representative agonist of GLP1R31. We observed significant reporter 
signals in both lines (Fig. 2a). The background signals of hGLP1R/LacZ-293 and hGLP1R/NLuc-293 (0 nM Ex4) 
were higher than that of HEK293 cells, probably due to leakage of LacZ or NLuc expression. Subsequently, we 
investigated whether the culture supernatants of Ex4-secreting yeast cells could activate the hGLP1R of hGLP1R/
LacZ-293 and hGLP1R/NLuc-293 cell lines. We cultured the cell lines with or without the culture supernatants of 
Figure 2. Functional cell-based assay for evaluating the reporter cell lines. (a) Functional cell-based assay using 
authentic exendin-4 (Ex4). hGLP1R/NLuc-293 and hGLP1R/LacZ-293 were cultured in DMEM media with 
or without 30 nM authentic Ex4. WT HEK293 was used as a control. Values are mean ± SD (n = 3). Two-tailed 
Student’s t-test was used to compare two groups (*p < 0.05, **p < 0.01). N.S., not significant. (b) Functional 
cell-based assay using culture supernatants of yeast cells secreting Ex4. hGLP1R/NLuc-293 and hGLP1R/
LacZ-293 were cultured in DMEM media with culture supernatants of yeast cells producing Ex4 (Yeast-Ex4) or 
WT yeast cells (Yeast-WT). Values are mean ± SD (n = 3). Two-tailed Student’s t-test was used to compare two 
groups (*p < 0.05, **p < 0.01). N.S., not significant.
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Ex4-secretory yeast (yeast-Ex4) or wild-type (WT) yeast (yeast-WT) and we observed significant reporter signals 
in both lines (Fig. 2b). Although the signal-noise ratio of hGLP1R/LacZ-293 was lower than that of hGLP1R/
NLuc-293, we concluded that hGLP1R/LacZ-293 could be used as a fluorescent reporter line for hGLP1R, 
because luciferase imaging has two drawbacks. First, we cannot detect luminescence if secreted luciferases run 
out of a limited amount of substrates in droplets. Second, the rate of photon production by luciferase is very low, 
hence luciferase imaging is not appropriate for high-throughput analysis.
Functional assay of hGLP1R using floating hGLP1R/LacZ-293 cells. In Fig. 1, we used adherent 
reporter cells for functional assays. However, when reporter cells are encapsulated in droplets, they are in sus-
pension. Therefore, we investigated hGLP1R of hGLP1R/LacZ-293 activity could be measured in suspension. 
We prepared floating hGLP1R/LacZ-293 cells in RPMI-1640 medium with or without 30 nM authentic Ex4. We 
observed a significant increase in fluorescence in the sample with authentic Ex4 (Fig. 3a). The result indicated 
that floating hGLP1R/LacZ-293 cells could respond to the activation of hGLP1R. Subsequently, we examined 
the potential of activating hGLP1R by co-culture with yeast cells secreting Ex4. We mixed yeast cells secreting 
Ex4 and hGLP1R/LacZ-293 cells in fresh RPMI-1640 containing LacZ substrate to obtain 4.5 × 105 cells/50 μL 
and 5 × 103 cells/50 μL, respectively. After incubation, we observed a significant increase in fluorescence when 
hGLP1R/LacZ-293 cells were co-cultured with yeast cells secreting Ex4 (Fig. 3b), suggesting the feasibility of 
functional cell-based assay by co-culture of hGLP1R/LacZ-293 and ligand-secreting yeast cells in droplets.
Development of a functional assay system using droplet microfluidics. To ascertain whether 
hGLP1R activity could be detected in droplets, mammalian hGLP1R/LacZ-293 cells were encapsulated in drop-
lets using various media: DMEM medium (no ligand), DMEM containing authentic Ex4 (Ex4), DMEM contain-
ing WT yeast cells (Yeast-WT), and DMEM containing yeast cells secreting Ex4 (Yeast-Ex4). After incubating the 
droplets at 30 °C for 6 h, we observed fluorescence using a confocal microscope (Fig. 4a). When hGLP1R/LacZ-
293 cells were encapsulated with authentic Ex4 or yeast cells secreting Ex4, significant increases in fluorescence 
intensity were observed (Fig. 4b). In the co-culture experiments, some droplets didn’t emit fluorescence. This is 
because droplets will emit fluorescence only when both yeast cells and mammalian reporter cells are encapsu-
lated. Furthermore, some reporter cells did not well respond to the addition of Ex4, and box plots of droplets with 
“no ligand” and that with “Ex4” was partially overlapped (Fig. 4b). This is probably because cultured mammalian 
cells can show different traits even when they are derived from a monoclonal cell population.
Subsequently, we evaluated whether yeast cells that activate the reporter cell line could be isolated using flu-
orescence microscopy analysis. WT yeast cells and yeast cells secreting Ex4 were mixed at a ratio of 100 to 1 and 
suspended in DMEM to a 9.1 × 106 yeast cells/mL concentration. The mixture of yeast cells was encapsulated 
in droplets with the reporter cell line adjusted to a 5.0 × 106 cells/mL concentration. The fluorescence intensi-
ties of droplets were quantified using a confocal microscope (Fig. 4c,d). We isolated single droplet with strong 
fluorescence, and cultured yeast cells among the droplet. Three colonies were formed on the plate media. Using 
colony-direct PCR, we observed that isolated yeast cells were Ex4-secreting cells (Fig. 4e and Supplementary 
Information 2), which indicated that we could isolate yeast cells secreting functional peptide ligands using the 
system.
Discovery of novel functional ligand sequences using droplet microfluidics. The N-terminal two 
amino acids of Ex4 are involved in the activation of GLP1R32,33, and mutations in the N-terminal two amino acids 
have resulted in decreases in agonist activity32,33. Therefore, we explored whether we could identify novel Ex4 
Figure 3. Functional cell-based assay using floating reporter cells. (a) Functional cell-based assay using 
authentic Exendin-4 (Ex4). The floating hGLP1R/LacZ-293 cells were suspended in a RPMI-1640 medium with 
or without 30 nM of authentic Ex4. Floating WT HEK293 was used as control. Values are mean ± SD (n = 3). 
Two-tailed Student’s t-test was used to compare two groups (*p < 0.05). N.S., not significant. (b) Functional 
cell-based assay by co-culture with yeast cells secreting Ex4. The floating mammalian hGLP1R/LacZ-293 or 
WT HEK293 cells were co-cultured with yeast cells producing Ex4 (Yeast-Ex4) or WT yeast cells (Yeast-WT). 
Values were mean ± SD (n = 3). Two-tailed Student’s t-test was used to compare two groups (*p < 0.05). N.S., 
not significant.
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Figure 4. High-throughput functional cell-based assay using droplet microfluidics. (a) Representative 
fluorescence micrographs of droplets. The hGLP1R/LacZ-293 cells were encapsulated with no ligand, 30 nM 
authentic Exendin-4 (Ex4), WT yeast cells (Yeast-WT, 9.1 × 106 cells/mL), or yeast cells producing Ex4 
(Yeast-Ex4, 9.1 × 106 cells/mL.). The images show the bright field images (upper image) and the fluorescence 
images (lower image). (b) Box plots of fluorescence intensity of each droplet in the experiment of (a). We 
analyzed at least 70 droplets containing a reporter cell for all samples. Statistical significance was determined by 
two-tailed Student’s t-test (**p < 0.01). N.S., not significant. (c) Box plots of fluorescence intensity of droplets. 
The hGLP1R/LacZ-293 cells were encapsulated with a mixture of yeast-WT cells and yeast-Ex4 cells at a ratio of 
100:1. (d) A representative fluorescence image of droplets in the experiment of (c). The images show the bright 
field image (upper image) and the fluorescence image (lower image). (e) A colony-direct PCR was performed 
on yeast cells isolated in the experiment of (c,d). To determine whether colonies isolated from the strongly 
fluorescent droplet were yeast-WT or yeast-Ex4, a colony-direct PCR was performed on isolated cells. Yeast-Ex4 
and yeast-WT were used as a positive control and a negative control, respectively.
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variant sequences randomized at the N-terminal two amino acids using a functional droplet assay system. We 
constructed a yeast library secreting randomized Ex4 variants using gap repair cloning34. In this study, we com-
pletely randomized two amino acids of N-terminus. It was expected that most mutant peptides were non-active, 
and that the original Ex4 appeared at the probability of 0.20% in the mutant library. We then encapsulated the 
yeast cells and the mammalian hGLP1R/LacZ-293 cells in droplets, and observed that some droplets exhibited 
strong fluorescence. We isolated six droplets from about one hundred thousand droplets and cultured yeast cells 
in separate YPD plates. Among a total of six plates, we obtained two plates with one colony (drop 1 and 2), one 
plate with three colonies (drop 3), one plate with two colonies (drop 4), and two plates with no colonies (drops 
5 and 6). We cultured the yeast cells, and their culture supernatants were added to adherent hGLP1R/NLuc-293 
cells to re-evaluate the activities of the peptides secreted by the yeast cells. At least one yeast cell in each droplet 
secreted a functional peptide ligand (Fig. 5a). The sequences of the ligands were determined by Sanger sequenc-
ing, and all peptides had an N-terminal sequence that was different from that of WT Ex4 (Fig. 5b).
To investigate whether the activity of the peptides was not influenced by the post-translational modifica-
tions by yeast or differences in secretion efficiencies, WT Ex4 and Ex4 variants fused with an N-terminal FLAG 
sequence were produced using Escherichia coli. The peptides were purified using anti-FLAG resin, and reacted 
with enterokinase, which cleaves the peptides after the FLAG sequence to expose free N-terminal of Ex4 pep-
tides. We added the purified WT Ex4 produced by E. coli with or without enterokinase reactions to the hGLP1R/
NLuc-293 cells, and observed a significant increase in luminescence only when the peptides were cleaved by 
enterokinase (Fig. 6a). The result indicated that WT Ex4 produced by E. coli is functional and a free N-terminal 
was vital for the activation of GLP1R. The amounts of the purified WT Ex4 and Ex4 variants produced by E. coli 
were then quantified using liquid chromatography coupled to mass spectrometry, and their activities were eval-
uated using the hGLP1R/NLuc-293 cells. The Ex4 variants produced by E. coli had an activation capacity higher 
or comparable to that of WT Ex4 produced by E. coli (Fig. 6b). Though we did not obtain a variant with an at least 
2-fold increased activity compared to Ex4, this is probably because Ex4 is a very strong agonist which was isolated 
from the venome of the Gila monster31, and we think it is worthwhile that we succeeded in improving the activity 
of such a strong agonist.
Discussion
In our previous study13, we developed a functional cell-based assay using a reporter mammalian cell line 
(hGLP1R/NLuc-293) and a yeast library secreting peptide ligand. However, the system used a luminescence 
assay system in a 96-well format, leading to low throughput. In the present study, we modified the system and 
replaced the reporter protein from NanoLuc with LacZ, which facilitates the evaluation of ligand activity using 
fluorescence. Although the replacement resulted in a decrease in the signal-noise ratio, we could identify func-
tional droplets using fluorescence microscopy (Fig. 4a and b). The replacement facilitated compatibility with 
fluorescence-activated sorting, which could lead to improvements in throughput identification of functional lig-
ands. In our co-culture assay system, compounds produced by yeast cells could affect the viability of mammalian 
cells. In our previous study, addition of culture supernatants of yeast cells containing GLP1R agonists successfully 
induced expression of NLuc of mammalian reporter cells13. In addition, this study showed that co-cultivation of 
yeast cells and mammalian cells could significantly increase reporter signals (Figs 3b and 4). Hence we assumed 
Figure 5. Functional evaluation of yeast cells producing randomized Exendin-4 (Ex4) variants isolated by 
high-throughput functional cell-based assay using droplet microfluidics. (a) Evaluation of the activity of the 
randomized Ex4 variants secreted by isolated yeast cells. The adherent hGLP1R/NLuc-293 cells were incubated 
with culture supernatants of the isolated yeast cells, and luminescence intensity was quantified. Yeast-Ex4 and 
Yeast-WT were used as a positive control and a negative control, respectively. Values were given as mean ± SD 
(n = 3). (b) Sequences of the isolated Ex4 variants. Amino acids shown in red indicate the N-terminal two 
amino acids.
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that potential toxicity of yeast metabolites didn’t disturb our purpose to screen yeast cells secreting functional lig-
ands. Ever if the mammalian reporter cells were dead, fluorescent molecules produced by LacZ continue existing 
in droplets, hence we could observe fluorescence signals and isolate yeast cells. In this study, we didn’t check how 
fast the hGLP1R/LacZ-293 cells respond to the activation of hGLP1R. Optimization of incubation times could 
lead to more quantitative evaluation of agonists’ activity which enables to distinguish strong agonist and weak 
agonist.
A droplet microfluidic device can produce highly monodisperse droplets in the nanometer to micrometer 
diameter range, at rates of tens of thousands of droplets per second22. In the present study, we optimized cell con-
centrations for better encapsulation of the reporter cells and yeast cells. Based on the results, the concentration 
of reporter cells was set to 5.0 × 106 cells/mL (Table S1) and that of yeast cells to 9.1 × 106 cells/mL (Table S2). At 
such concentrations, the probability that at least one mammalian cell was included in a droplet was 6.55%, and 
the probability that at least one yeast cell was included in a droplet was 11.29%, hence the probability that both 
were included in a droplet was 0.74%. In our previous study, we separately cultured each ligand-secreting yeast 
mutant, and manually transferred culture supernatants to a 96-well plate13, hence it was very laborious to evaluate 
even one hundred of yeast mutants. The droplet-based approach developed in this study enabled us to evaluate 
thousands of ligand-secreting yeast mutants, because the microfluidics device could generate droplets containing 
both mammalian reporter cells and ligand-secreting yeast cells at a speed of about several tens of droplets/sec. 
Although we manually observed droplets with a fluorescence microscope, we could evaluate ten times or more 
ligand-secreting yeast mutants compared to the previous study.
Figure 6. Functional evaluation of Exendin-4 (Ex4) variants produced by E. coli. (a) The functional assay 
using WT Ex4 produced by E. coli. We cultured E. coli producing WT Ex4 fused with a FLAG sequence at the 
N-terminal (E. coli-Ex4) and WT E. coli (E. coli-WT). The cell lysates were purified using anti-FLAG resin, 
reacted with or without enterokinase, and assayed with the adherent hGLP1R/NLuc-293 cells. DMEM media 
with or without 3 nM authentic Ex4 were used as a positive control and a negative control. Values are mean ± SD 
(n = 3). Two-tailed Student’s t-test was used to compare two groups (**p < 0.01). N.S., not significant. (b) 
Activities of each of the Ex4 variants produced by E. coli. Relative luminescence units were corrected based on 
concentrations of each peptide. Values are mean ± SD (n = 3). Two-tailed Student’s t-test was used to compare 
two groups (*p < 0.05, **p < 0.01). N.S., not significant.
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To provide proof-of-principle for our system, we attempt to identify novel ligand sequences using a rand-
omized yeast library. In our experiments, we isolated six droplets and recovered yeast cells from four droplets 
(Fig. 5a). Some single yeast cells were assumed to have been lost during the isolation process using a microman-
ipulator. We also found that some droplets included several yeast cells (Fig. 5a), which could be because multiple 
cells can be encapsulated in one droplet (Table S2). To exclude such non-specific yeast cells, screening yeast cells 
over several cycles can be beneficial35.
Based on the results of the experiments using E. coli as a host for producing peptides, we demonstrated that 
the activities of the identified Ex4 variants were not influenced by post-translational modifications or differences 
in secretion efficiencies (Fig. 6b). A previous study revealed that the hydrogen bonding of Glu387 of GLP1R and 
histidine at the N-terminus of the ligand is vital for the activity of GLP1R32. In the present study, functional pep-
tides contained Ser (Fig. 6b, peptide 1) or Thr (Fig. 6b, peptide 4) at the N-terminus, suggesting that the amino 
acids were selected due to hydrogen bonding with hGLP1R.
It is considered that further improvement of the throughput will be necessary to comprehensive characteri-
zation of the peptide’s mutation space. To improve the throughput, there is a method for increasing the genera-
tion speed of droplets36 and methods of increasing the proportions of droplets containing cells29,37. In addition, 
fluorescence-activated cell sorting on a microfluidics will improve the throughput to retrieve fluorescence-positive 
droplets.
In conclusion, we demonstrated that functional assay of hGLP1R could be performed by temporarily 
co-culturing the reporter mammalian cells and the yeast cells in a bulk assay. In addition, we encapsulated the 
mammalian cells and yeast cells in water-in-oil droplets using a droplet microfluidic device for high-throughput 
identification of peptide ligands against hGLP1R. We identified novel functional ligands, one of which exhibited 
higher activity than that of Ex4 (Fig. 6b, peptide 2). The result suggested that the droplet assay system constructed 
in the present study could be effective in the identification of novel peptide ligands. In future studies, we will 
optimize our system to improve encapsulation efficiency and throughput by combining fluorescence-activated 
sorting and next-generation sequencers.
Methods
Construction of reporter cells. To construct a reporter cell line that constitutively produces human GLP1R 
(hGLP1R) and inducibily secretes NanoLuc in response to the activation of hGLP1R, pIRES-hGLP1R, and 
pCRE-NLuc13, were co-transfected in HEK293 cells (European Collection of Cell Culture, Salisbury, UK) using 
Xfect™ (Clontech Laboratries, Inc., Mountain View, CA, USA). The transfected cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Nacalai Tesque, Kyoto, Japan) containing 10% FBS (GE Healthcare, Little 
Chalfont, UK), 1% penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, USA), 400 µg/mL G418 (Nacalai 
Tesque), and 0.1 µg/mL puromycin (Wako Pure Chemical Industries, Osaka, Japan). The reporter cells were 
selected to establish a stable cell line harboring GLP1R and secretory NanoLuc genes (hGLP1R/NLuc-293)13. To 
construct a reporter cell line that secretes LacZ in response to the activation of hGLP1R, pIRES-hGLP1R13, and 
pCRE-LacZ were co-transfected in HEK293 cells, and a reporter cell line, hGLP1R/LacZ-293, was selected using 
a medium containing G418 and puromycin. A full sequence of pIRES-hGLP1R and partial sequences of pCRE-
NLuc and pCRE-LacZ are provided in Supplementary Information 3.
Construction of yeast cells secreting peptide ligands. Saccharomyces cerevisiae BY4742 [MATα, 
his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0] (GE Healthcare) was used for the secretion of a hGLP1R agonist, Exendin-4 
(Ex4, produced by the Gila monster31) and randomized Ex4 variants. To construct an Ex4-secretory yeast, 
pULS-Ex413 was transformed into the BY4742 strain using the Frozen-EZ Yeast Transformation-II Kit (Zymo 
Research, Orange, CA, USA). Yeast cells secreting randomized Ex4 variants were constructed using gap repair 
cloning34 as follows. pULS plasmid13 was digested with EcoRI and KpnI to obtain a linear vector fragment. Insert 
DNA fragments encoding Ex4 genes whose two N-terminal amino acids were randomized were PCR-amplified 
from pULS-Ex4 using the following primers: 5 ′- GC CA GC AT TG CT GC TA AA GA AG AA GG GG TA TC TT T 
G GA TA AA AG AN NK NN KG AAGGAACATTTACCAGTGACTTGTC-3′ and 5′-AGTCTCTTTCTCGG 
TCTAGCTAGTTTTACT-3′. The BY4742 strains were transformed using the linear vector fragments (500 ng) 
and the randomized insert fragments (250 ng) for gap repair cloning. The transformants were selected on syn-
thetic dextrose solid (SDC) medium without uracil [0.67% (w/v), yeast nitrogen base without amino acids, 2% 
(w/v) glucose, 1% (w/v) casamino acids, 0.002% (w/v) adenine, 0.002% (w/v) l-tryptophan, and 2% (w/v) agar]. 
Full sequences of the plasmids used in the present study are provided in Supplementary Information 3.
Construction of E. coli strains producing peptide ligands. pKPY51438, with an isopropyl-β- 
d-thiogalactoside (IPTG) inducible T5 promoter, was a gift from David Tirrell (Addgene plasmid #62598; http://
n2t.net/addgene:62598; RRID:Addgene_62598). pKPY514 was digested using EcoRI and HindIII to obtain a linear 
vector fragment. Plasmids encoding Ex4 variants fused with a FLAG sequence at the N-terminus were obtained 
using In-Fusion® HD Cloning Kit (Clontech Laboratries, Inc.). The resultant plasmids were named pKPY-Ex4, 
pKPY-FS-Ex4, pKPY-HA-Ex4, pKPY-AL-Ex4, pKPY-TG-Ex4, and pKPY-SC-Ex4. E. coli BL21 Star (DE3) [F- ompT 
hsdSB (rB-mB-) gal dcm rne131 (DE3)] (Thermo Fisher Scientific, Waltham, MA, USA) was used for the production 
of WT Ex4 and Ex4 variants. The transformants were selected on Luria-Bertani (LB) medium [1% (w/v) tryptone, 
0.5% (w/v) yeast extract, 1% (w/v) sodium chloride, and 2% (w/v) agarose] containing 50 µg/mL kanamycin. Full 
sequences of pKPY514 and pKPY-Ex4 and partial sequences of the other plasmids are provided in Supplementary 
Information 3.
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Preparation of media containing hGLP1R ligands secreted by yeast cells. To prepare media con-
taining hGLP1R ligands secreted by yeast cells, the yeast cells were cultured in a 96-well plate (Thermo Fisher 
Scientific) containing 300 μL of SDC medium at 30 °C for 48 h. Thereafter, yeast cells were spun down and the 
medium was exchanged with 250 μL DMEM or RPMI-1640 (Nacalai Tesque) and incubated at 30 °C for 12 h. 
DMEM medium was used when the reporter cells were in an adherent state and RPMI-1640 medium was used 
when the reporter cells were in suspension.
Activation of hGLP1R in various experimental procedures. To perform a functional assay using the 
adherent hGLP1R/NLuc-293 cell line, hGLP1R/NLuc-293 cells were seeded at 5 × 103 cells/100 µL in a 96-well 
plate (Thermo Fisher Scientific) and cultured at 37 °C for 24 h. Thereafter, the medium was exchanged with 50 µL 
DMEM containing a hGLP1R ligand, and further cultured at 37 °C for 12 h. Afterwards, 50 µL luciferase substrate 
(Nano-Glo™ Luciferase Assay System, Promega, Fitchburg, WI, USA) was added, and luminescence intensity was 
measured using a Fluoroskan Ascent™ Microplate Fluorometer (Thermo Fisher Scientific).
To perform a  functional assay using the adherent hGLP1R/LacZ-293 cell line, hGLP1R/LacZ-293 
cells were seeded at 5 × 103 cells/100 µL in a 96-well plate (Thermo Fisher Scientific) and cultured at 37 °C 
for 24 h. The medium was then exchanged with 50 µL DMEM containing a hGLP1R ligand and 50 µM 
5-chloromethylfluorescein di-β-D-galactopyranoside (CMFDG, Thermo Fisher Scientific). After 12 h incubation 
at 37 °C, fluorescence intensity was measured using Fluoroskan Ascent™ Microplate Fluorometer.
An assay using floating hGLP1R/LacZ-293 was carried out using the following procedure. The hGLP1R/LacZ-
293 cells were suspended in RPMI-1640 medium containing a hGLP1R ligand and CMFDG (50 µM) at a con-
centration of 5 × 103 cells/50 µL and then adequately stirred by pipetting. Immediately after the modification, the 
solution was placed in a 96-well plate and incubated at 37 °C for 12 h, and fluorescence intensity was measured.
Co-culture of floating hGLP1R/LacZ-293 and ligand-secreting yeast cells was carried out using the following 
procedure. The yeast cells were suspended in 5 mL SDC medium and cultured at 37 °C for 6 h. Thereafter, the 
yeast cells and hGLP1R/LacZ-293 cells were suspended in RPMI-1640 to obtain 4.5 × 105 cells/50 µL and 5 × 103 
cells/50 µL, respectively. CMFDG was then added to the medium to a volume of 50 µM and adequately stirred by 
pipetting. Immediately after the modification, the solution was incubated in a 96-well plate at 37 °C for 12 h, and 
fluorescence intensity was measured.
Functional cell-based assay in droplet. A single-inlet microfluidic device was designed according to 
previous reports39,40 (Fig. S1). In brief, polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning Corp, Midland, 
MI, USA) and its cross-linker were mixed at a ratio of 10:1 (w/w), degassed, poured onto a master mold, and 
cured. The cured PDMS was peeled from the mold and punched with 0.75 mm biopsy punch (World Precision 
Instruments, Sarasota, FL, USA). The PDMS slab was bonded to a glass slide by plasma treatment (Plasma 
Cleaner PDG-32G; Harrick Scientific, Pleasantville, NY, USA), and baked for at least 30 min at 70 °C. The micro-
fluidics device, an air compressor, Mitos P-Pump Basic (Dolomite, Charleston, MA, USA) were connected, and 
the pressure was set to be about 150 mbar for aqueous phase and about 300 mbar for oil phase. To generate drop-
lets, cell suspension and a carrier phase (FC40 containing 5% (v/v) of the surfactant Pico-Surf1, Dolomite), were 
pumped into the cross-junction.
To investigate the optimal concentration of hGLP1R/LacZ-293 cells for droplet encapsulation, hGLP1R/LacZ-
293 cells were stained using 20 µg/mL 4′6-diamidino-2-phenylindole dihydrochloride (DAPI, Nacalai Tesque). 
The stained cells were then suspended in PBS to obtain 1.0 × 106, 2.5 × 106, 5.0 × 106, 7.5 × 106, and 10 × 106 
cells/mL. The suspensions were enclosed in droplets using the single inlet microfluidic device39,40. The number 
of cells encapsulated in each droplet was determined by image analysis using a confocal microscope (Fig. S2 and 
Table S1). To investigate the optimal concentration of yeast cells for droplet encapsulation, S. cerevisiae BY4742 
cells were stained using Fungi-Fluor (Polysciences, Inc., Warrington, PA, USA), and suspended in PBS 1.9 × 106, 
5.5 × 106, 9.1 × 106, 12.7 × 106, and 16.3 × 106 cells/mL concentrations. The number of cells encapsulated in 
each droplet was determined by image analysis using a confocal microscope (Fig. S3 and Table S2). In addition, 
dividing or aggregated yeast cells populations were determined by observing same yeast suspension (Fig. S4 and 
Table S3).
As a proof-of-principle experiment, hGLP1R/LacZ-293 was suspended at 5.0 × 106 cells/mL in the following 
media: DMEM, DMEM containing authentic Ex4, DMEM containing WT S. cerevisiae (Yeast-WT), or DMEM 
containing Ex4-secreting S. cerevisiae (Yeast-Ex4). The concentration of yeast cells was set to be 9.1 × 106 cells/
mL. CMFDG was added in the media to realize a concentration of 50 µM. After encapsulation, the droplets were 
incubated at 30 °C for 6 h. Fluorescence intensity of each droplet was calculated by image analysis under a confo-
cal laser scanning fluorescence microscope.
As a competitive assay, yeast-WT and yeast-Ex4 were mixed at a ratio of 100 to 1 in DMEM at 9.1 × 106 cells/
mL with 50 µM CMFDG. hGLP1R/LacZ-293 cells were suspended in the solution at a 5.0 × 106 cells/mL concen-
tration. The solution was enclosed in droplets, and incubated at 37 °C for 6 h. Fluorescence intensity was calculated 
by image analysis. In addition, single droplet emitting strong fluorescence was isolated using a micromanipulator 
(Drummond Scientific Co., Broomall, PA, USA), and incubated in 200 µL of YPD medium at 30 °C for 4 h. The 
yeast cells were then cultured on YPD plate medium. Colony-direct PCR was performed using the following PCR 
primers: 5′-GCCAGCATTGCTGCTAAAGAAGAAG-3′ and 5′-CCAAGTCGACTTACGATGGTG-3′.
High-throughput evaluation of Ex4 variants using droplet microfluidics. A yeast library pro-
ducing Ex4 variants constructed by gap repair cloning was cultured in SDC medium at 30 °C for 6 h. hGLP1R/
LacZ-293 cells and the yeast cells were then suspended in RPMI-1640 medium with 50 µM CMFDG to obtain 
5.0 × 106 cells/mL and 9.1 × 106 cells/mL concentrations, respectively. The medium was enclosed in droplets, 
and incubated at 37 °C for 6 h. Then, 10 μL of the droplets were put on a slide glass. We manually observed about 
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20 thousand droplets with a fluorescence microscope (IX71, Olympus, Tokyo, Japan), and a droplet with strong 
fluorescence was isolated by a micromanipulator (Drummond Scientific Co.). This process was repeated six times 
to isolate six fluorescence droplets. Yeast cells in the fluorescence droplets were isolated as described above. The 
sequences of isolated Ex4 variants were determined by Sanger sequencing.
To verify the activities of the identified Ex4 variants, we prepared variant peptides using E. coli as follows. 
E. coli strains harboring plasmids encoding Ex4 variants were cultured in 5 mL LB medium containing 50 µg/
mL kanamycin. Thereafter, 500 μL of the culture solution was added to 5 mL fresh LB medium and the solution 
incubated at 37 °C for 1 h. IPTG was then added to the solution to obtain a final volume of 1 mM, and E. coli cells 
were further cultured for 4 h. The E. coli cells were suspended in 150 μL PBS and disrupted using Bioruptor UCD-
250 (Cosmo Bio Co., Ltd., Tokyo, Japan). The ligand peptides were purified using ANTI-FLAG M2 Affinity Gel 
(Sigma-Aldrich), digested with enterokinase, and diluted 100-fold with DMEM medium. The resultant solutions 
were used as media containing hGLP1R ligands produced by E. coli. The purified ligands were mixed with adher-
ent hGLP1R/NLuc-293 to confirm their activities. Concentrations of the ligands were determined using selected 
reaction-monitoring against FLAG peptides using liquid chromatography (Nexera UHPLC/HPLC System; 
Shimadzu, Kyoto, Japan)-triple-quadrupole mass spectrometry (LCMS-8060; Shimadzu). The calibration curve 
used for quantification was obtained with standard FLAG peptides (Wako Pure Chemical Industries).
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